Kutty Selva Nandakumar Selected Research

Arthritis (Polyarthritis)

5/2022	Characterization of chronic relapsing antibody mediated arthritis in mice with a mutation in Ncf1 causing reduced oxidative burst.
1/2021	Targeted inhibition of ATP5B gene prevents bone erosion in collagen-induced arthritis by inhibiting osteoclastogenesis.
1/2021	'SMASH' recommendations for standardised microscopic arthritis scoring of histological sections from inflammatory arthritis animal models.
1/2021	Genetic dissection of a major haplotype associated with arthritis reveal FcγR2b and FcγR3 to act additively.
10/2020	Vitamin D3 receptor polymorphisms regulate T cells and T cell-dependent inflammatory diseases.
6/2020	Phytoestrogens protect joints in collagen induced arthritis by increasing IgG glycosylation and reducing osteoclast activation.
1/2020	Cartilage-binding antibodies initiate joint inflammation and promote chronic erosive arthritis.
1/2020	Molecular and Cellular Pathways Contributing to Joint Damage in Rheumatoid Arthritis.
6/2019	Protective effects of Wang-Bi tablet on bone destruction in collagen-induced arthritis by regulating osteoclast-osteoblast functions.
1/2019	Autoantibodies as Diagnostic Markers and Mediator of Joint Inflammation in Arthritis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kutty Selva Nandakumar Research Topics

Disease

63	Arthritis (Polyarthritis) 05/2022 - 09/2002
33	Rheumatoid Arthritis 05/2022 - 09/2002
29	Experimental Arthritis 01/2021 - 09/2002
28	Inflammation (Inflammations) 01/2022 - 03/2005
10	Autoimmune Diseases (Autoimmune Disease) 01/2021 - 10/2007
7	Neoplasms (Cancer) 12/2021 - 05/2019
4	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2022 - 09/2014
4	Infections 04/2021 - 02/2018
4	Bone Resorption 01/2021 - 10/2019
4	Communicable Diseases (Infectious Diseases) 12/2018 - 02/2013
3	Pain (Aches) 01/2019 - 04/2016
2	Mitochondrial Diseases (Mitochondrial Disease) 01/2022 - 01/2021
2	Necrosis 01/2021 - 08/2010
2	Osteoarthritis 06/2020 - 09/2002
2	Dengue (Dengue Fever) 05/2020 - 02/2018
2	Systemic Lupus Erythematosus (Libman-Sacks Disease) 09/2019 - 09/2002
2	Hypersensitivity (Allergy) 01/2019 - 03/2011
2	Joint Diseases (Joint Disease) 09/2013 - 09/2002
1	Chronic Disease (Chronic Diseases) 05/2022
1	COVID-19 01/2022
1	Hyperpigmentation 12/2021
1	Skin Diseases (Skin Disease) 12/2021
1	Premature Aging 12/2021
1	Atopic Dermatitis (Atopic Eczema) 12/2021
1	Acne Vulgaris 12/2021
1	Zika Virus Infection 09/2021
1	Human Influenza (Influenza) 04/2021
1	Hypoglycemia (Reactive Hypoglycemia) 01/2021
1	Dyslipidemias (Dyslipidemia) 01/2021
1	Hyperuricemia 12/2020

Drug/Important Bio-Agent (IBA)

39	Collagen Type II (Type II Collagen)IBA 05/2022 - 09/2002
28	AntibodiesIBA 01/2021 - 09/2002
23	CollagenIBA 01/2021 - 01/2004
15	AutoantibodiesIBA 05/2022 - 09/2002
14	Monoclonal AntibodiesIBA 05/2022 - 09/2002
14	EpitopesIBA 01/2020 - 09/2002
12	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2006
12	Immunoglobulin G (IgG)IBA 06/2020 - 09/2002
10	CytokinesIBA 01/2022 - 10/2002
8	VaccinesIBA 01/2022 - 10/2010
6	Antigen-Antibody Complex (Immune Complex)IBA 01/2019 - 07/2004
6	Peptides (Polypeptides)IBA 01/2019 - 10/2003
6	PolymersIBA 01/2016 - 11/2011
5	MannansIBA 05/2022 - 09/2014
5	Cartilage Oligomeric Matrix ProteinIBA 01/2020 - 01/2008
5	AntigensIBA 01/2019 - 10/2007
5	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2016 - 10/2007
4	LigandsIBA 10/2020 - 08/2010
4	LipopolysaccharidesIBA 01/2020 - 11/2003
4	EnzymesIBA 02/2018 - 03/2006
4	Polysaccharides (Glycans)IBA 02/2018 - 10/2007
4	poly-N-isopropylacrylamideIBA 01/2016 - 11/2011
4	AutoantigensIBA 08/2015 - 01/2006
3	Estrogens (Estrogen)FDA Link 01/2022 - 11/2003
3	Antiviral Agents (Antivirals)IBA 04/2021 - 02/2018
3	Therapeutic UsesIBA 06/2019 - 07/2004
3	AsparagineIBA 01/2018 - 10/2007
2	neutrophil cytosolic factor 1IBA 05/2022 - 10/2007
2	MicroRNAs (MicroRNA)IBA 01/2022 - 12/2021
2	Estrogen ReceptorsIBA 01/2022 - 01/2021
2	Messenger RNA (mRNA)IBA 01/2022 - 01/2020
2	ChemokinesIBA 01/2022 - 04/2016
2	pristane (pristan)IBA 01/2021 - 01/2016
2	Collagen Type XIIBA 01/2020 - 01/2018
2	Pharmaceutical PreparationsIBA 09/2019 - 01/2007
2	Toll-Like Receptor 2IBA 05/2019 - 07/2012
2	B-Lymphocyte Epitopes (B-Cell Epitope)IBA 01/2018 - 08/2015
2	Acetylglucosaminidase (NAGase)IBA 01/2018 - 06/2013
2	acetyl 4-aminosalicylic acidIBA 08/2014 - 01/2010
2	Toll-Like Receptors (Toll-Like Receptor)IBA 03/2014 - 11/2011
2	Proteoglycans (Proteoglycan)IBA 03/2013 - 06/2011
2	NADP (NADPH)IBA 07/2012 - 11/2011
2	NADPH Oxidases (NAD(P)H oxidase)IBA 07/2012 - 09/2009
2	N-isopropylacrylamideIBA 12/2011 - 11/2011
2	Amino Acids FDA Link 01/2008 - 09/2002
2	CryogelsIBA 07/2007 - 01/2005
2	Interleukin-4 (Interleukin 4)IBA 06/2006 - 10/2002
2	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 03/2006 - 03/2005
1	Cytochromes c (Cytochrome c)IBA 01/2022
1	Inactivated VaccinesIBA 01/2022
1	Caspase 3 (Caspase-3)IBA 01/2022
1	NAD (NADH)IBA 01/2022
1	CosmeceuticalsIBA 12/2021
1	Hemagglutinins (Hemagglutinin)IBA 04/2021
1	Neuraminidase (Sialidase)IBA 04/2021
1	Membrane Proteins (Integral Membrane Proteins)IBA 04/2021
1	IgG Receptors (Fc gamma RI)IBA 01/2021
1	GlobulinsIBA 01/2021
1	Protons (Proton)IBA 01/2021
1	FlavonoidsIBA 01/2021
1	AlbuminsIBA 01/2021
1	Adenosine Triphosphate (ATP)IBA 01/2021
1	Actins (F Actin)IBA 01/2021
1	Biological ProductsIBA 01/2021
1	AdipokinesIBA 01/2021

Therapy/Procedure

6	Therapeutics 12/2021 - 03/2014
3	Injections 05/2022 - 03/2005
3	Intravenous Injections 05/2022 - 07/2004
2	Immunotherapy 10/2021 - 01/2021
2	Intraperitoneal Injections 01/2018 - 09/2005